Product Center
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-13
- Views:
(Summary description)On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan.
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched
(Summary description)On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-13 14:26
- Views:
On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. This marks the official entry of the company's first Class I new drug, which has received dual approvals from both Chinese and U.S. regulatory authorities, into a new phase of clinical development. It also represents another significant milestone in Ab&B Bio's steady fulfillment of its R&D pipeline commitments and continuous strengthening of its financial foundation.
Respiratory syncytial virus (RSV) is one of the primary pathogens causing respiratory infections in infants, children, and the elderly, leading to conditions such as pneumonia and bronchitis. The infection is most prevalent among children under 5 years of age and individuals aged 60 years and older. According to research statistics, a significant number of children and elderly individuals worldwide are hospitalized or even die annually due to RSV infection. However, there are currently no specific therapeutic agents for RSV disease, and management of acute infections primarily relies on supportive care. Vaccination has thus become the preferred clinical intervention for RSV prevention and control.
The recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-based) (adjuvant) under investigation in this clinical trial employs big data analytics to enhance drug-like potential research, utilizing proprietary innovative technologies and a highly stable pre-F antigen sequence. Preclinical studies demonstrated that the vaccine not only stimulates the production of high-titer neutralizing antibodies against both RSV A2 and B strains but also induces robust cellular immune responses. In murine challenge protection studies, the vaccine reduced viral load in the lungs below the detection limit, exhibiting significant protective efficacy without evidence of vaccine-enhanced disease (VED), indicating high safety profiles. Additionally, the pre-F antigen structure exhibits exceptional thermal stability, eliminating the need for lyophilization and allowing long-term storage at 2–8°C in liquid form, thereby optimizing the manufacturing process for streamlined and efficient commercial production.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
